1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioVaxys Technology Corp.

BioVaxys Technology Corp.

BVAXF
BioVaxys Technology Corp.US flagOther OTC
0.11
USD
-0.01
- -
3.21MMarket Cap
BioVaxys Technology Corp.
BVAXF
(Other OTC)

Recent

price

0.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.22
-0.42
-0.78
-1.19
-0.57
-0.2
-0.25
Basic EPS, GAAP
- -
-0.22
-0.43
-0.64
-0.16
-0.08
-0.2
-0.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.17
3.26
0.81
-0.26
-0.4
-0.21
-0.2
Book Value per Share
- -
0.18
0.77
0.09
-0.08
-0.25
-0.1
-0.11
Tangible Book Value per Share
- -
1
3
8
10
13
20
26
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-1
-6
-12
-8
-4
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
2
1
-1
-3
-2
-3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
10
8
-1
-3
-2
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-25.07
-81.12
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'24
Jan'25
Apr'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
29
29
Market Capitalization
14
16
8

Working Capital

FRC

•

in mil. unless spec.
Oct'24
Jan'25
Apr'25
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
4
Payables & Accruals
3
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1,019.39%
-43.06%
Free Cash Flow
- -
187.35%
276.83%
Net Income, GAAP
- -
171.77%
-48.55%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.08
-0.11
-0.02
- -
-0.57
2024
0.04
-0.03
-0.05
- -
-0.2
2025
-0.04
-0.05
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
EQRx, Inc. (EQRX)
Bavarian Nordic A/S (BAVA.CO)
uniQure N.V. (QURE)
InMed Pharmaceuticals Inc. (IN.TO)
Actuate Therapeutics Inc (ACTU)
Helix BioPharma Corp. (HBPCF)
Business
I did a web search but did not find direct recent news or changes specifically for BioVaxys Technology Corp. (Ticker: BVAXF). I will now search specifically about BioVaxys Technology Corp.’s business activities, products, services, and any recent updates or developments to gather relevant detailed information.

Company News

APIChatGPT

  • thenewswire.com

    BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

  • thenewswire.com

    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

  • thenewswire.com

    BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

  • thenewswire.com

    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

  • thenewswire.com

    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

  • thenewswire.com

    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

  • thenewswire.com

    BioVaxys Announces Application for Management Cease Trade Order

  • thenewswire.com

    BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

  • newsfilecorp.com

    BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

  • thenewswire.com

    BioVaxys 1Q2026 R&D and Collaborative Activity

  • newsfilecorp.com

    BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

  • thenewswire.com

    2025 Corporate Review

  • newsfilecorp.com

    BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

  • thenewswire.com

    BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D

  • thenewswire.com

    BioVaxys Technology Corp. Closes Debt Settlement Transaction

  • businesswire.com

    BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

  • thenewswire.com

    BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

  • prnewswire.com

    BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

  • newsfilecorp.com

    CSE Bulletin: Consolidation - BioVaxys Technology Corp. (BIOV)

  • prnewswire.com

    BIOVAXYS ANNOUNCES SHARE CONSOLIDATION